Combination of Tumor M2-PK with S100-beta

Combination of plasma Tumor M2-PK and serum S100-beta
determinations improves estimation of prognosis in melanoma.

marker combination	probability of overall survival 14 month after blood withdrawal
S100-β ≤ 0.12 μg/ml Tumor M2-PK ≤ 15 U/ml	0.98 ( n = 204)
S100-β ≤ 0.12 μg/ml Tumor M2-PK > 15 U/ml	0.95 ( n = 36)
S100-β > 0.12 μg/ml Tumor M2-PK ≤ 15 U/ml	0.58 ( n = 39)
S100-β > 0.12 μg/ml Tumor M2-PK > 15 U/ml	0.27 ( n = 21)

Tumor M2-PK concentrations were measured in EDTA plasma with a sandwich ELISA from ScheBo Biotech AG Giessen, Germany.


	S100-beta concentrations were measured in serum with a sandwich immunoluminometric assay (LIA-mat Sangtec 100) from Sangtec Medical, Bromma, Sweden).

	Tumor M2-PK and S100-beta measurements: Selma Ugurel

	References Tumor M2-PK: correlations in melanoma Metabolic tools for tumor diagnosis Pyruvate kinase isoenzymes: M2-PK